|

Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer

RECRUITINGN/ASponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Actively Recruiting
PhaseN/A
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
Started2023-05-24
Est. completion2027-12-31
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05673304

Summary

IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost associated with neoadjuvant chemotherapy (NAC). As a secondary objective, histochemical and molecular analysis of the tumour and the inflammatory microenvironment will be performed.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Luminal B-like BC, cT1-2
* Indication for neoadjuvant chemotherapy

Exclusion Criteria:

* Pregnancy
* Breast feeding
* Patient not available for follow up

Conditions3

Breast CancerCancerRadiotherapy

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.